Lupus is a chronic autoimmune disease that disproportionately affects racial and ethnically minoritized populations, ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

People with lupus have a higher risk of hearing loss due to inflammation that can damage the inner ear and auditory pathways. Hearing loss is a lesser-known complication of lupus, but it can ...

Your gut microbiome can trigger an immune response, leading to chronic systemic inflammation and lupus. Here are some tips to ...

Aurinia Pharma and partner Otsuka have secured approval in the EU for Lupkynis, billed as the first oral treatment for active nephritis in patients with the autoimmune disease systemic lupus ...

HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual’s risk for flares and retinal toxicity. GC are used as ‘bridging therapy’ ...

Systemic lupus erythematosus (SLE) is a latent, insidious autoimmune disease, and with the development of gene sequencing in recent years, our study aims to develop a gene-based predictive model to ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...